Maximum dose: 16 mg per dose
Ondansetron is a selective 5-HT3 receptor antagonist
Take this medicine only as directed
Ondansetron is in a class of medications called
What Is Zofran? Zofran (ondansetron) is an antiemetic and selective 5-HT3 receptor antagonist prescribed for the treatment of nausea and vomiting due to
Use: Ondansetron oral liquid is used for the treatment of chemotherapy-induced nausea and vomiting, radiation-induced nausea and vomiting, and
The ondansetron dosage
Uses of Zofran: It is used to treat or prevent upset stomach and throwing up
Prevention of nausea and vomiting associated with initial and repeat courses of
The first dose of ondansetron is usually taken 30 minutes before the start of chemotherapy, 1 to Ondansetron is a prescription drug
Table 1: Adult Recommended Dosage Regimen for Prevention of Nausea and Vomiting
Ondansetron HCl dihydrate is a white to off-white powder that is soluble in water and normal saline
जानिए Ondansetron Tablet in Hindi की जानकारी, लाभ, फायदे, उपयोग, प्रयोग, कीमत, कब Ondansetron is commonly used for preventing nausea and vomiting
Pediatric (4-11 years): 5 ml (4 mg) Ondansetron Oral Solution should be taken 30 minutes before the start of chemotherapy
Table 1: Adult Recommended Dosage Regimen for Prevention of Nausea and Vomiting Indication Dosage Regimen Highly Emetogenic Cancer Chemotherapy A single 24 mg dose administered 30 minutes before
The active ingredient in ZOFRAN tablets and ZOFRAN oral solution is ondansetron hydrochloride as the dihydrate, the racemic form of ondansetron and a selective blocking agent of the serotonin 5-HT 3 receptor type
To reduce the risk of dizziness चक्कर आना, सांस की कमी महसूस होना, बेहोशी, तेज हार्ट रेट
24, (95% CI 1
Monitor for decreased bowel activity, particularly in patients with risk factors for gastrointestinal obstruction
Common Zofran side effects may include: diarrhea or constipation; headache; drowsiness; or
Ondansetron oral solution is a 5-HT 3 receptor antagonist indicated for the prevention of: nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2
For moderately emetogenic chemotherapy, an 8mg dose is administered 30 minutes